U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Insulin detemir, a long-acting human insulin analog, is sold under the brand name LEVEMIR to improve glycemic control in adults and children with diabetes mellitus. Insulin detemir binds to the insulin receptor. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. The primary activity of insulin detemir is the regulation of glucose metabolism. Insulin detemir crosses the BBB and reduces food intake, it improves weight management by an enhanced and prolonged centrally mediated reduction of energy intake.

CNS Activity

Approval Year

2005
131
Targets

Targets

Primary TargetPharmacologyConditionPotency
Insulin receptor
13
Target ID: P06213
Gene ID: 3643.0
Gene Symbol: INSR
Target Organism: Homo sapiens (Human)
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
LEVEMIR

Approved Use

Levemir is indicated to improve glycemic control in adults and children with diabetes mellitus.

Launch Date

2005
PubMed

PubMed

TitleDatePubMed
Tissue selectivity of insulin detemir action in vivo.
2006 Jun
Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.
2008 Sep
Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor.
2010 Aug
COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
2017 Sep

Sample Use Guides

In Vivo Use Guide
LEVEMIR (Insulin detemir) is a recombinant human insulin analog for once- or twice-daily subcutaneous administration. Patients treated with LEVEMIR once-daily should administer the dose with the evening meal or at bedtime. Patients who require twice-daily dosing can administer the evening dose with the evening meal, at bedtime, or 12 hours after the morning dose. The dose of LEVEMIR must be individualized based on clinical response. Blood glucose monitoring is essential in all patients receiving insulin therapy
Route of Administration: Other
Name Type Language
INSULIN DETEMIR
EMA EPAR   INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
INSULIN B29(N-MYRISTOYL-LYS)-B30(DES-THR) HUMAN RECOMBINANT
Common Name English
LEVEMIR
Brand Name English
29(SUP B)-(N(SUP 6)-(1-OXOTETRADECYL)-L-LYSINE)-(1(SUP A)-21(SUP A)),(1(SUP B)-29(SUP B))-INSULIN (HUMAN)
Common Name English
INSULIN,DETEMIR,HUMAN [VANDF]
Common Name English
INSULIN DETEMIR [USAN]
Common Name English
29(SUP B)-(N(SUP 6)-MYRISTOYL-L-LYSINE)-30(SUP B)-DE-L-THREONINEINSULIN (HUMAN)
Common Name English
DETEMIR
Common Name English
N.EPSILON.B29-TETRADECANOYL DES(B30) HUMAN INSULIN
Common Name English
INSULIN,DETEMIR,HUMAN
VANDF  
Common Name English
INSULIN DETEMIR [EMA EPAR]
Common Name English
(1A-21A),(1B-29B)-INSULIN (HUMAN), 29B-(N6-(1-OXOTETRADECYL)-L-LYSINE)-, RECOMBINANT
Common Name English
INSULIN DETEMIR [MI]
Common Name English
insulin detemir [INN]
Common Name English
INSULIN DETEMIR RECOMBINANT [ORANGE BOOK]
Common Name English
NN-304
Code English
INSULIN DETEMIR [JAN]
Common Name English
INSULIN DETEMIR RECOMBINANT
ORANGE BOOK  
Common Name English
Insulin detemir [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175453
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
NDF-RT N0000004931
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
WHO-VATC QA10AE05
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
NDF-RT N0000004931
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
NDF-RT N0000004931
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
WHO-ATC A10AE05
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
NCI_THESAURUS C581
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
Code System Code Type Description
DAILYMED
4FT78T86XV
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
MERCK INDEX
m6296
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C65920
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104391
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
EVMPD
SUB02692MIG
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
RXCUI
139825
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY RxNorm
MESH
C105111
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
INN
7735
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
CAS
169148-63-4
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
DRUG BANK
DB01307
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
WIKIPEDIA
INSULIN DETEMIR
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
USAN
KK-28
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
SMS_ID
100000089418
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
PUBCHEM
16137271
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
FDA UNII
4FT78T86XV
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
DRUG CENTRAL
4985
Created by admin on Sat Dec 16 00:14:45 GMT 2023 , Edited by admin on Sat Dec 16 00:14:45 GMT 2023
PRIMARY
ACTIVE MOIETY
INSULIN DETEMIR
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966